BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23020707)

  • 21. Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients.
    Vidal J; Clavé S; de Muga S; González I; Pijuan L; Gimeno J; Remón J; Reguart N; Viñolas N; Gironés R; Bernet L; Majem M; Bosch-Barrera J; Porta R; Alonso N; Palmero R; Taus A; Albanell J; Espinet B; Salido M; Arriola E
    J Thorac Oncol; 2014 Dec; 9(12):1816-20. PubMed ID: 25393795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma.
    Nakamura H; Tsuta K; Yoshida A; Shibata T; Wakai S; Asamura H; Furuta K; Tsuda H
    J Clin Pathol; 2013 Aug; 66(8):705-7. PubMed ID: 23618692
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Copy number gain in recurrent anaplastic lymphoma kinase (ALK) rearrangement-lung adenocarcinoma in the pleural effusion.
    Abe H; Kawahara A; Azuma K; Murakami Y; Takase Y; Naito Y; Akiba J
    Diagn Cytopathol; 2018 Sep; 46(9):744-747. PubMed ID: 29637735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small non-mucinous bronchioloalveolar carcinoma with anaplastic lymphoma kinase immunoreactivity: a novel ALK fusion gene?
    Yamamoto M; Takeuchi K; Shimoji M; Maniwa T; Isaka M; Nakagawa K; Ohde Y; Kondo H; Nakajima T
    Cancer Sci; 2012 Feb; 103(2):390-2. PubMed ID: 22296236
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer.
    Preusser M; Berghoff AS; Ilhan-Mutlu A; Magerle M; Dinhof C; Widhalm G; Dieckmann K; Marosi C; Wöhrer A; Hackl M; Zöchbauer-Müller S; von Deimling A; Schoppmann SF; Zielinski CC; Streubel B; Birner P
    Lung Cancer; 2013 Jun; 80(3):278-83. PubMed ID: 23453647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ALK status in a primary lung tumour and metachronous metastases.
    Salido M; Pijuan L; Galván AB; Gimeno J; Cañadas I; Rodriguez-Rivera M; Rojo F; Albanell J; Solé F; Arriola E
    Histopathology; 2012 Apr; 60(5):843-5. PubMed ID: 22236334
    [No Abstract]   [Full Text] [Related]  

  • 27. Anaplastic lymphoma kinase gene analysis as a useful tool for identifying primary unknown metastatic lung adenocarcinoma.
    Watanabe N; Ishii T; Takahama T; Tadokoro A; Kanaji N; Dobashi H; Bandoh S
    Intern Med; 2014; 53(23):2711-5. PubMed ID: 25447655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytomorphology of non-small cell lung carcinoma with anaplastic lymphoma kinase gene rearrangement.
    Toll AD; Maleki Z
    Diagn Cytopathol; 2015 Jan; 43(1):8-15. PubMed ID: 24723496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ALK testing in lung adenocarcinoma: technical aspects to improve FISH evaluation in daily practice.
    Martin V; Bernasconi B; Merlo E; Balzarini P; Vermi W; Riva A; Chiaravalli AM; Frattini M; Sahnane N; Facchetti F; Mazzucchelli L; Sessa F; Tibiletti MG
    J Thorac Oncol; 2015 Apr; 10(4):595-602. PubMed ID: 25514802
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer.
    Yatabe Y; Takahashi T; Mitsudomi T
    Cancer Res; 2008 Apr; 68(7):2106-11. PubMed ID: 18381415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer.
    Lira ME; Kim TM; Huang D; Deng S; Koh Y; Jang B; Go H; Lee SH; Chung DH; Kim WH; Schoenmakers EF; Choi YL; Park K; Ahn JS; Sun JM; Ahn MJ; Kim DW; Mao M
    J Mol Diagn; 2013 Jan; 15(1):51-61. PubMed ID: 23246132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases.
    Warnecke-Eberz U; Bollschweiler E; Drebber U; Pohl A; Baldus SE; Hoelscher AH; Metzger R
    Oncol Rep; 2008 Sep; 20(3):619-24. PubMed ID: 18695914
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.
    Lin E; Li L; Guan Y; Soriano R; Rivers CS; Mohan S; Pandita A; Tang J; Modrusan Z
    Mol Cancer Res; 2009 Sep; 7(9):1466-76. PubMed ID: 19737969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes.
    Prenzel KL; Baldus SE; Mönig SP; Tack D; Sinning JM; Gutschow CA; Grass G; Schneider PM; Dienes HP; Hölscher AH
    Cancer; 2004 May; 100(9):1909-17. PubMed ID: 15112272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.
    Cooper WA; O'toole S; Boyer M; Horvath L; Mahar A
    Pathology; 2011 Feb; 43(2):103-15. PubMed ID: 21233671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme.
    Marchetti A; Barberis M; Papotti M; Rossi G; Franco R; Malatesta S; Buttitta F; Ardizzoni A; Crinò L; Gridelli C; Taddei GL; Clemente C; Scagliotti G; Normanno N; Pinto C
    J Thorac Oncol; 2014 Oct; 9(10):1470-6. PubMed ID: 25170637
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Homogeneity and High Concordance of ALK Translocation in Primary Lung Adenocarcinoma and Paired Lymph Node Metastasis.
    Ma W; Guo L; Shan L; Liu X; Lyu N; Ying J
    Sci Rep; 2017 Sep; 7(1):10961. PubMed ID: 28887531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers.
    Chang YL; Wu CT; Shih JY; Lee YC
    Ann Surg Oncol; 2011 Feb; 18(2):543-50. PubMed ID: 20811949
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.
    Tiseo M; Gelsomino F; Boggiani D; Bortesi B; Bartolotti M; Bozzetti C; Sammarelli G; Thai E; Ardizzoni A
    Lung Cancer; 2011 Feb; 71(2):241-3. PubMed ID: 21168933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer.
    Hsu NY; Ho HC; Chow KC; Lin TY; Shih CS; Wang LS; Tsai CM
    Cancer Res; 2001 Mar; 61(6):2727-31. PubMed ID: 11289154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.